Introduction
In the 20 years since Michel Mirowski and coworkers implanted an ICD into their first patient [1] , the implantable cardioverter defibrillator (ICD) has become recognized as the therapy of first choice for managing patients at high risk of sudden cardiac death from ventricular tachyarrhythmias. Multiple clinical series and recently completed prospective, randomized trials have shown that ICDs are irrefutably superior to antiarrhythmic drugs in reducing sudden death, and improving overall survival [2] [3] [4] [5] [6] . Furthermore, major technological advances have made the implant and follow-up of ICDs nearly as simple and straightforward as with pacemakers. Figure 1 shows the rapid increase in numbers of patients receiving ICDs, as well as some of the major technological milestones and important studies, which have contributed to this growth.
But, when one looks deeper into the impressive increase in ICD use, it becomes evident that it is largely U.S.A. driven (Fig. 2) . It is this polarized 1998  1996  1995  1994  1993  1992  1991  1990  1989  1988  1987  1986  1985  1984  1982  1981  1980 adoption of ICD therapy -reflecting vastly different implant rates in Europe and in the U.S.A. -which is the focus of our paper. We will show below that epidemiological factors cannot account for this approximate five fold difference in ICD implantation rates. This point is underscored by the fact that the rates of adoption of related cardiovascular device interventions -as will also be shown hereafter -do not show such huge variations, as is seen with the ICD. So, it would appear that the disparity in the use of this remarkable therapy is truly a 'European enigma', a phenomenon unique in medicine, which warrants at the very least a critical look at possible causes, and speculation on what the future may bring. Figure 3 depicts the rates for cardiovascular deaths in 1995 in the major European countries, and in the U.S.A. There are some notable differences, varying from lows of 2·5 and 3·1 cardiovascular deaths per 1000 population in France and Spain to highs of 4·0 in the U.K. and 4·3 in Germany, respectively. What is interesting is that the mean rates for cardiovascular deaths were exactly the same: 3·6 in Europe and in the U.S.A.!
Epidemiology

Device interventions
Approximately four patients out of five suffering from ventricular tachyarrhythmias, and therefore potential candidates for ICDs, have coronary artery disease as their underlying cause. Thus, ICD use should be correlated with interventions such as PTCA*, pacemaker implantation, and heart valve surgery. A pacemaker, although not used primarily for disease related to underlying coronary disease, is a very similar therapeutic device with which ICD utilization can be compared. Figure 4 compares the mean rates for each of these interventions in Europe and in the U.S.A. during 1999. The utilization rate for PTCA, pacemakers and heart valves (per million population) are seen to be approximately 50% of those for the U.S.A., but for ICDs, Europe's rate is only one-fifth that in the U.S.A. A poignant example comes from comparing pacemaker and ICD use in the two continents. Pacemaker use in Europe lags the U.S.A. rate by a little over 40%, whereas usage *We have taken data for PTCA use, rather than coronary stenting, simply because the former is a 'mature' therapy with fairly stable usage rates, whereas rates of stent use are still undergoing great yearly and regional fluctuations. beginning (the first European implants were undertaken by Coumel and co-workers in 1982, followed by Breithardt, Klein and others in 1984). There is no evident difference favouring the U.S.A. in terms of publications and clinical trials on new ICD models or features. In fact, the two earliest randomized, prospective trials of the use of an ICD vs antiarrhythmic drug therapy for secondary prevention of (sudden) mortality began in Germany and Holland [7, 8] .
ICD Guidelines
One area in which the U.S.A. has been far more pro-active with regard to ICDs is in terms of regularly updating the official guidelines (see Table 1 ) [9] . Here it is important to emphasize that such guidelines, by definition, emanate from general clinical consensus, not vice-versa. Of course, a natural consequence of clinicians reaching such agreements is the increased application of these guidelines by other physicians and institutions. Perhaps just as importantly, these guidelines serve to provide clinicians with much stronger arguments to deal with their respective health reimbursement authorities. Applying this process to the ICD situation, our American colleagues acknowledge the importance of the guidelines (including FDA approval) in their dealings with the Health Care Financing Agency (HCFA) and third party private insurance organizations such as Blue Cross or Blue Shield. With each new set of guidelines as listed in the table, physicians in the U.S.A. were able to offer ICD therapy to larger or new groups of at-risk patients. The most recent revision of these guidelines, published by the AHA/ACC and endorsed by NASPE, was published in April 1998 [10] . In contrast, the most recent official European guidelines were written 1991 [11] and have not been revised until now. In the absence of updated guidelines incorporating the considerable body of new science, physicians in Europe have had to negotiate on their own with their hospital administrations and/or health authorities, an obviously much weaker bargaining position than their U.S.A. colleagues who could avail themselves of published medical society support. [12] ( Fig. 5) actually showed that -due to significant reductions in re-hospitalization following ICD implantation -the costs for an ICD are essentially 'amortized' within about a year and a half, leading Levy to write an editorial entitled, 'Is the ICD cost-effective?' [13] . Looking at this question critically, there are numerous medical interventions carried out routinely in Europe with less favourable costeffectiveness than ICD therapy: kidney dialysis in the elderly, surgery for single vessel coronary artery disease, liver transplantation, etc. The table below from Steinhaus et al. [14] indicates the range of cost-effectiveness (in terms of 'life-years-saved') of commonly practiced interventions in the U.S.A. The costs of these interventions would be fairly similar in Europe, and show the ICD at or below the cost-effectiveness of these other therapies.
The Dutch cost-effectiveness study [15] showed significant cost impact related to the high mortality and high rate of cross-overs to ICDs of patients randomized to conventional therapy. The difference in mortality (35% for conventional therapy, vs 14% for ICD therapy) led to the final conclusions: $94 per day alive for conventional therapy patients, compared to $63 for the ICD '. . . a net $11,300 (saved costs) per patient per life-year-saved. ' The MADIT costeffectiveness study, in which the ICD-randomized patients benefited by 0·86 year increased longevity compared to the drug-treated group (mostly amiodarone), resulted in the overall cost-effectiveness ratio of $12 500 per life-year saved (for transvenous implantations, with devices lasting d4 years) [16] . For their respective studies, Wever et al. and Mushlin et al. emphasized that quality-of-life evaluations enhanced the quality life year cost-effectiveness ratios favouring ICD treatment. We pointed out several years ago that the cost-effectiveness of the ICD was intimately .) =pre-ICD; =post-ICD. related to the risk group of patients being treated, with patients having high arrhythmic risk naturally showing much more favourable cost-effectiveness than cohorts at relatively low risk [17] . This same point has been illustrated in the Markhov model study by Owens et al. [18] , showing that for risk groups where ICD reduces mortality by 40% or more, its costeffectiveness is under $30k per life year saved (as in MADIT); in contrast, the cost-effectiveness ratio for a lower risk group, where the ICD advantage is only 20% exceeds $60k*. Stanton and Bell have recently published a thorough critical analysis of the ICD cost-effectiveness issue [19] . They have shown the pitfalls in some cost-effectiveness analyses (e.g. AVID [20] ), which have 'truncated' the period of follow-up so the costs of effective long-term therapies have been largely paid for, but not yet had sufficient follow-up time to demonstrate that benefit. They concluded, based on a review of all the published cost-effectiveness studies, that the 'break-even' period for ICD therapy varies between 1 and 3 years (time by which the up-front and follow-up costs for ICD therapy equal -in terms of cost per life-yearssaved -those for antiarrhythmic drug therapy).
A final point concerning cost-effectiveness comes from the above-mentioned Swiss study [12] . All the guidelines now agree that treatment for sustained, symptomatic ventricular tachycarda is a major therapeutic objective of ICDs, in addition to its use in preventing sudden death. Unfortunately, this factor is not accounted for at all in the cost-effectiveness studies, which are based exclusively on mortality reductions. [24] , but only recently, and it is probable that these may similarly raise awareness and interest in ICD therapy in the coming years.
Education, awareness of sudden death and ICD therapy
Future expectations
Belgium, the Netherlands and Germany have each recently issued revised sets of ICD guidelines [25] [26] [27] , each more or less reflecting the ACC/AHA guidelines in effect in the U.S.A. since early 1998. New guidelines in France are reportedly nearly completed. A study group of the European Society of Cardiology has just finalized a new official 'European guidelines' which is anticipated imminently. While there will certainly continue to be nuance differences between these national and international guidelines, we know already that there must be generally good agreement, since essentially they all take into account the same body of clinical and trial evidence. It is also probable *Sensitivity analysis, assuming ICD generator life-time d4 years and peri-op mortality c1%.
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that the 1998 U.S.A. guidelines will undergo further revision. For instance, based on the persuasive results from MUSTT, it is probable that the 4th Class 1A indication shown in Table 1 (the so-called 'MADIT indication') will be relaxed, deleting the requirement to show non-responsiveness in the electrophysiology laboratory to a class 1A drug, such as procainamide.
As indicated above, 'guidelines' are certainly not the entire explanation for the observed disparity in ICD use between the two continents. Nevertheless, these new and forthcoming guidelines, taken by practicing cardiologists as a firm endorsement of the important studies mentioned above, will certainly have some impact in improving the current trends. Beyond this, we also anticipate that MUSTT will have a much stronger and more immediate impact than the previous studies, on European physicians' attitudes.
Final remarks
The evidence favouring ICD therapy, coming from the accumulated clinical experience and underscored by the multiple randomized, prospective trials has and is moving European leaders to officially acknowledge the role of the ICD, either as primary therapy, or a serious option in patients at risk of sudden death. This fact, coupled with the continuing technological improvements in the devices, making their implantation and follow-up ever more similar to pacemakers, will undoubtedly lead current ICD implanters to increase their numbers and new institutions to begin with the therapy. Cost-saving measures -both at the implanting centres (e.g. minimal pre-and post-implant tests) and hospitalization -as well as price concessions from the manufacturers, as the numbers of devices increases, should further support the growth of ICD therapy in Europe.
